Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) does not directly cause sun sensitivity as a recognised side effect in its licensed prescribing information — that's the short answer. The confusion is understandable, because some medicines genuinely do increase photosensitivity, and the question of whether tirzepatide joins that list circulates widely online. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber assesses suitability before any treatment starts, and they can address any specific concerns about sun exposure during your consultation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the misconception worth addressing first. True drug-induced photosensitivity (where a medicine chemically lowers your skin's tolerance to UV) is a real phenomenon associated with certain antibiotics, diuretics and non-steroidal anti-inflammatory drugs. Tirzepatide is not in that group. The NHS tirzepatide medicines page lists the recognised side effects in plain language, and photosensitivity does not appear. The SmPC (the detailed prescribing document that every licensed medicine carries) echoes this: increased sensitivity to sunlight is not a documented adverse reaction for Mounjaro at any dose.
So where does the worry come from? Partly from cross-contamination with GLP-1 medicines that have more established sun-related cautions, and partly from individual anecdotes posted online about redness and skin flushing, symptoms that have other, more straightforward explanations. Nausea, warmth and flushing are recognised gastrointestinal and vascular effects of the medicine that some people notice; they are not the same as UV hypersensitivity.
If you've read that Mounjaro and the sun are a dangerous combination, the evidence does not currently support that framing. For deeper reading on what the research does and doesn't show, our page exploring whether Mounjaro makes you more sensitive to the sun goes into the clinical detail, as does our page on whether Mounjaro makes you burn in the sun.
There is one genuinely practical sun-related point, and it concerns injection sites rather than your overall skin. Tirzepatide is injected subcutaneously into the abdomen, thigh or upper arm. The injection site often shows a small area of redness, mild swelling or tenderness in the hours after the dose. Exposing that localised inflammation to direct, intense sunlight before it settles can make the irritation more uncomfortable and may contribute to uneven pigmentation over repeated cycles. Standard advice applies: keep the injection area out of direct sun for at least the first day after dosing, or cover it with loose clothing.
Storage is a related practical concern in warm weather. Each Mounjaro KwikPen must be kept refrigerated between 2–8°C; many people find the fridge door the most convenient spot for their current pen. If a pen gets too warm (left in a hot car or a sun-facing bag) it may be damaged. Always check the Patient Information Leaflet for the exact permitted room-temperature window before travelling; never rely on online summaries for this detail.
Our broader guide to Mounjaro and sun exposure covers storage in warm climates and travel scenarios in more detail.
Hot weather raises your fluid needs. Tirzepatide slows gastric emptying and can blunt hunger and thirst signals, which means some people on the medicine drink less than they realise, particularly in the first weeks at a new dose. Add a warm day, physical activity or even just a commute in a heatwave, and the deficit accumulates faster than expected.
Dehydration on tirzepatide carries an additional concern: the medicine's gastrointestinal side effects (nausea, vomiting, diarrhoea) can themselves cause fluid loss, and heat compounds that. The NHS England guidance on weight-management injections specifically flags dehydration as something to guard against.
Practical steps in summer: set reminders to drink water, carry a bottle, and if you do have a period of significant vomiting or diarrhoea in hot weather, treat it as more urgent than you might otherwise. Seek medical advice early rather than waiting it out. This isn't unique to Mounjaro (it applies to the whole class) but it is worth actively managing in warmer months.
For a wider picture of how tirzepatide works and what to expect, our tirzepatide therapy page is a good starting point.
This isn't strictly a sun question, but it comes up alongside summer-lifestyle queries. Women taking oral contraceptive pills alongside tirzepatide are advised to use an additional non-oral contraceptive method (such as condoms) for the first four weeks of treatment and for four weeks after each dose increase. This is because slowed gastric emptying may reduce how reliably the pill is absorbed. Summer travel, routine disruption and missed doses are also times when this matters more. Our page on Mounjaro and contraception options explains the practicalities, including why a coil may be worth considering.
If you're on Mounjaro and have specific questions about how your other medications interact with the medicine, a prescriber is the right person to ask. You can also review the overall Mounjaro treatment information on our site for a fuller picture before starting your conversation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.